We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Fundus Autofluorescence Patterns in Stargardt Disease Over Time

R. Theodore Smith, MD, PhD
Arch Ophthalmol. 2012;130(10):1354-1355. doi:10.1001/archophthalmol.2012.1559.
Text Size: A A A
Published online


The recent article by Cukras et al1 that demonstrated interesting centrifugal “trajectories” for hyperautofluorescent flecks in Stargardt disease enhances our understanding of the progression of this disease and bears on fundamental questions about the role of lipofuscin. Given the importance of these issues, I suggest that the reference therein to related quantitative work2 should also be amplified. We specifically investigated the spatial predictive value of hyperautofluorescent lesions for the subsequent development of hypoautofluorescence or atrophy in the same location with precise registration and segmentation of serial images as well as statistical calculation of spatial predictive values. To our knowledge, this is the only such study, and the results were surprising. If toxic effects to the retinal pigment epithelium by excess lipofuscin drives Stargardt disease, then flecks, with high lipofuscin levels, should be more likely to turn atrophic than neighboring background. However, the predictive value of hyperautofluorescent lesions for future hypoautofluorescence or atrophy at a given location was actually less than background, suggesting that an elevated level of lipofuscin, while an important marker for Stargardt disease, may not be a major cause.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





October 1, 2012
Catherine A. Cukras, MD, PhD; Wai T. Wong, MD, PhD; Rafael Caruso, MD; Denise Cunningham, MS; Wadih Zein, MD; Paul Sieving, MD
Arch Ophthalmol. 2012;130(10):1354-1355. doi:10.1001/archophthalmol.2012.2008.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.